FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3114143889> ?p ?o ?g. }

• W3114143889 endingPage "1170" @default.
• W3114143889 startingPage "1166" @default.
• W3114143889 abstract "Behcet syndrome (BS) is a chronic systemic inflammatory disorder involving vessels of all sizes, characterized by relapsing episodes of oral and/or genital ulcers, as well as skin lesions. Ocular, vascular, gastrointestinal, neurological system involvement can cause significant morbidity and mortality. Glucocorticoids and immunosuppressants are the cornerstones for the management of BS. Biologic agents has been recommended for severe and/or refractory BS. Interferon-α (IFN-α) had multiple biological effects, such as antiviral and antiproliferative, that could regulate both innate and adaptive immunity in BS. Growing evidence showed the efficacy of IFN-α in severe and/or refractory BS. Many studies have demonstrated that IFN-α has comparable effectiveness and tolerance profiles as anti-tumor necrosis factor (TNF) agents for Behcet's uveitis with a much lower cost and steroid-and immunosuppressant-sparing effects. IFN-α has been recommended as second-line therapy for ocular involvement of BS in EULAR (The European League Against Rheumatism) 2018. IFN-α also improves mucocutaneous lesions in BS with the dosage from 3 to 9-12 million IU three times per week. A few cases indicated the therapeutic potential of IFN-α in intestinal BS. As a new trial of IFN-α in vascular BS (VBS), a recent study revealed the lower relapse rate and higher recanalization rate with IFN-α in lower extremity deep vein thrombosis (DVT). Another two case reports presented the efficacy of IFN-α in pulmonary artery involvement in BS. Also, case reports have shown successful treatment in refractory neurological involvement. There are two subtypes of IFN-α commonly used in autoimmune diseases, named IFN-α2a and IFN-α2b. IFN-α2a seemed more effective than IFN-α2b, especially in ocular and mucocutaneous involvement of BS. Side effects of IFN-α are dose-dependent and not severe. The most frequent side effects are flu-like syndrome, mild leukopenia and alopecia. Considering the potential risk of tuberculosis (TB) and hepatitis B virus (HBV) reactivation of TNF-α inhibitors, IFN-α is safe due to its anti-HBV effect and protective effect on TB. In conclusion, IFN-α is a promising choice for severe and/or refractory BS patients, especially for those who are intolerant or contraindicant to other biological agents, such as TNF inhibitors. Further prospective controlled studies are warranted to confirm the efficacy and safety of IFN-α in BS." @default.
• W3114143889 created "2021-01-05" @default.
• W3114143889 creator A5005451961 @default.
• W3114143889 creator A5008382096 @default.
• W3114143889 date "2020-12-18" @default.
• W3114143889 modified "2023-09-26" @default.
• W3114143889 title "[Progress in interferon: A treatment of Behcet syndrome]." @default.
• W3114143889 cites W1884885884 @default.
• W3114143889 cites W1979534455 @default.
• W3114143889 cites W1981124806 @default.
• W3114143889 cites W1983279918 @default.
• W3114143889 cites W2000104469 @default.
• W3114143889 cites W2003078384 @default.
• W3114143889 cites W2008345204 @default.
• W3114143889 cites W2035677339 @default.
• W3114143889 cites W2040235283 @default.
• W3114143889 cites W2041995906 @default.
• W3114143889 cites W2052004574 @default.
• W3114143889 cites W2061401593 @default.
• W3114143889 cites W2064729318 @default.
• W3114143889 cites W2067499731 @default.
• W3114143889 cites W2094175327 @default.
• W3114143889 cites W2097556922 @default.
• W3114143889 cites W2097603404 @default.
• W3114143889 cites W2099200878 @default.
• W3114143889 cites W2099726337 @default.
• W3114143889 cites W2101116471 @default.
• W3114143889 cites W2101126063 @default.
• W3114143889 cites W2106684817 @default.
• W3114143889 cites W2121119865 @default.
• W3114143889 cites W2130776189 @default.
• W3114143889 cites W2138481462 @default.
• W3114143889 cites W2145271539 @default.
• W3114143889 cites W2145765879 @default.
• W3114143889 cites W2177943720 @default.
• W3114143889 cites W2187341310 @default.
• W3114143889 cites W2320779290 @default.
• W3114143889 cites W2396480784 @default.
• W3114143889 cites W2405919165 @default.
• W3114143889 cites W2550856303 @default.
• W3114143889 cites W2606884288 @default.
• W3114143889 cites W2621003511 @default.
• W3114143889 cites W2786984319 @default.
• W3114143889 cites W2795891386 @default.
• W3114143889 cites W2800381948 @default.
• W3114143889 cites W2801666689 @default.
• W3114143889 cites W2803648300 @default.
• W3114143889 cites W2804866854 @default.
• W3114143889 cites W2886729415 @default.
• W3114143889 cites W2886996794 @default.
• W3114143889 cites W2907245605 @default.
• W3114143889 cites W2912113125 @default.
• W3114143889 cites W2944549872 @default.
• W3114143889 cites W2948553855 @default.
• W3114143889 cites W2955930629 @default.
• W3114143889 cites W2963988335 @default.
• W3114143889 cites W2972846107 @default.
• W3114143889 doi "https://doi.org/10.19723/j.issn.1671-167x.2020.06.032" @default.
• W3114143889 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7745276" @default.
• W3114143889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33331331" @default.
• W3114143889 hasPublicationYear "2020" @default.
• W3114143889 type Work @default.
• W3114143889 sameAs 3114143889 @default.
• W3114143889 citedByCount "0" @default.
• W3114143889 crossrefType "journal-article" @default.
• W3114143889 hasAuthorship W3114143889A5005451961 @default.
• W3114143889 hasAuthorship W3114143889A5008382096 @default.
• W3114143889 hasConcept C126322002 @default.
• W3114143889 hasConcept C141071460 @default.
• W3114143889 hasConcept C156662089 @default.
• W3114143889 hasConcept C203014093 @default.
• W3114143889 hasConcept C2776178377 @default.
• W3114143889 hasConcept C2777489490 @default.
• W3114143889 hasConcept C2778959117 @default.
• W3114143889 hasConcept C2779134260 @default.
• W3114143889 hasConcept C2780868729 @default.
• W3114143889 hasConcept C71924100 @default.
• W3114143889 hasConcept C90924648 @default.
• W3114143889 hasConceptScore W3114143889C126322002 @default.
• W3114143889 hasConceptScore W3114143889C141071460 @default.
• W3114143889 hasConceptScore W3114143889C156662089 @default.
• W3114143889 hasConceptScore W3114143889C203014093 @default.
• W3114143889 hasConceptScore W3114143889C2776178377 @default.
• W3114143889 hasConceptScore W3114143889C2777489490 @default.
• W3114143889 hasConceptScore W3114143889C2778959117 @default.
• W3114143889 hasConceptScore W3114143889C2779134260 @default.
• W3114143889 hasConceptScore W3114143889C2780868729 @default.
• W3114143889 hasConceptScore W3114143889C71924100 @default.
• W3114143889 hasConceptScore W3114143889C90924648 @default.
• W3114143889 hasIssue "6" @default.
• W3114143889 hasLocation W31141438891 @default.
• W3114143889 hasOpenAccess W3114143889 @default.
• W3114143889 hasPrimaryLocation W31141438891 @default.
• W3114143889 hasRelatedWork W1498499351 @default.
• W3114143889 hasRelatedWork W1524785835 @default.
• W3114143889 hasRelatedWork W2038311371 @default.
• W3114143889 hasRelatedWork W2062739102 @default.
• W3114143889 hasRelatedWork W2066337849 @default.

• next